https://glpagonists.com/news.html#story-0a GLP Agonists en 2026-05-14 Foundayo (orforglipron) clears phase 3 cardiovascular safety analysis 2026-05-14 0.9 https://glpagonists.com/news.html#story-0b GLP Agonists en 2026-05-08 Multiple state pharmacy boards open formal investigations into mass-market GLP-1 compounding operations 2026-05-08 0.9 https://glpagonists.com/news.html#story-0c GLP Agonists en 2026-05-03 FDA shortage-resolution enforcement now fully in effect for 503B compounded semaglutide and tirzepatide 2026-05-03 0.9 https://glpagonists.com/news.html#story-0d GLP Agonists en 2026-04-28 CMS expands Part D coverage of GLP-1s for cardiovascular indications 2026-04-28 0.9